Navigation Links
Onyx Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
Date:3/11/2011

EMERYVILLE, Calif., March 11, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Barclays Capital 2011 Global Healthcare Conference on Thursday, March 17, 2011 at 10:15 a.m. Eastern Time (7:15 a.m. Pacific Time).  

Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software.  For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through March 31, 2011.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals, Inc. Congratulates R&B and Pop Icon Gloria Gaynor, Named Woman of the Year by Arthritis Foundation
2. Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March
3. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
4. Valeant Pharmaceuticals Completes Acquisition of PharmaSwiss S.A.
5. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
6. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
7. Amylin Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
8. Isis Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
9. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
10. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
11. Jazz Pharmaceuticals to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):